Merit Medical Systems (NASDAQ:MMSI) Given New $115.00 Price Target at Barrington Research

Merit Medical Systems (NASDAQ:MMSI) had its target price raised by Barrington Research from $114.00 to $115.00 in a research report sent to investors on Wednesday,Benzinga reports. Barrington Research currently has an outperform rating on the medical instruments supplier’s stock. Barrington Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.96 EPS, Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $3.82 EPS and FY2026 earnings at $4.30 EPS.

Several other equities analysts have also recently issued reports on MMSI. Wells Fargo & Company upgraded shares of Merit Medical Systems from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $103.00 to $120.00 in a research note on Wednesday, December 11th. Piper Sandler increased their target price on shares of Merit Medical Systems from $110.00 to $114.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 21st. StockNews.com lowered Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Canaccord Genuity Group increased their price target on Merit Medical Systems from $125.00 to $127.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, Raymond James upped their target price on Merit Medical Systems from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 31st. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $109.80.

Merit Medical Systems Price Performance

Shares of MMSI opened at $108.88 on Wednesday. The business’s 50-day moving average is $101.47 and its two-hundred day moving average is $97.13. The company has a market capitalization of $6.35 billion, a P/E ratio of 53.37, a P/E/G ratio of 2.42 and a beta of 0.85. Merit Medical Systems has a fifty-two week low of $70.70 and a fifty-two week high of $111.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company had revenue of $339.85 million during the quarter, compared to analysts’ expectations of $334.60 million. During the same period last year, the business earned $0.75 earnings per share. Merit Medical Systems’s quarterly revenue was up 7.8% on a year-over-year basis. Research analysts predict that Merit Medical Systems will post 3.37 earnings per share for the current year.

Insider Buying and Selling at Merit Medical Systems

In other news, CFO Raul Jr. Parra sold 29,646 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total value of $2,905,900.92. Following the transaction, the chief financial officer now directly owns 16,361 shares of the company’s stock, valued at approximately $1,603,705.22. This trade represents a 64.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director F. Ann Millner sold 12,500 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the completion of the sale, the director now owns 32,391 shares of the company’s stock, valued at approximately $3,289,306.05. The trade was a 27.85 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC boosted its position in shares of Merit Medical Systems by 1.7% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 2,289,148 shares of the medical instruments supplier’s stock valued at $226,236,000 after acquiring an additional 38,780 shares during the last quarter. State Street Corp boosted its holdings in Merit Medical Systems by 0.7% in the 3rd quarter. State Street Corp now owns 2,231,701 shares of the medical instruments supplier’s stock valued at $220,559,000 after purchasing an additional 15,098 shares during the last quarter. FMR LLC grew its stake in shares of Merit Medical Systems by 70.1% in the 3rd quarter. FMR LLC now owns 1,577,246 shares of the medical instruments supplier’s stock valued at $155,879,000 after buying an additional 649,799 shares during the period. Geode Capital Management LLC increased its holdings in shares of Merit Medical Systems by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,265 shares of the medical instruments supplier’s stock worth $134,165,000 after buying an additional 17,490 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Merit Medical Systems by 8.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 727,340 shares of the medical instruments supplier’s stock valued at $71,883,000 after buying an additional 54,122 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.